5 assets in Duodenum Cancer

Therapeutic assets addressing Duodenum Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
N-Butyl Cyanoacrylate Duodenum Cancer	Minia University	P3	B (60)
Cyclophosphamide Duodenum Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Fludarabine Duodenum Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Kras Tcr-Transduced Pbl Duodenum Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Pantoprazole Duodenum Cancer	Washington University School of Medicine	P2	CCC (53)